End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma
Summary Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end‐point for...
Saved in:
| Published in | British journal of haematology Vol. 198; no. 2; pp. 333 - 337 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.07.2022
Wiley |
| Series | British Journal of Haematology |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Summary
Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end‐point for PFS. Our objective was to further evaluate surrogacy of CR measured by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial‐level surrogacy examining the association between treatment effects on EoI‐PET‐CR and PFS was evaluated using linear regression (RWLS2) and bivariate Copula (RCopula2) models. Although EoI‐PET‐CR strongly predicted PFS at a prognostic level, the trial‐level assessment did not show strong correlation (RWLS2=0.56, confidence interval [CI]: 0.20–0.88; RCopula2=0.35, CI: 0.0–0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI‐PET‐CR end‐point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET‐CR based surrogate end‐points is still warranted. |
|---|---|
| AbstractList | Progression-free survival (PFS) has been the regulatory primary end-point for recent phase III trials in first-line follicular lymphoma (FL), but requires prolonged follow-up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end-point for PFS. Our objective was to further evaluate surrogacy of CR measured by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial-level surrogacy examining the association between treatment effects on EoI-PET-CR and PFS was evaluated using linear regression () and bivariate Copula () models. Although EoI-PET-CR strongly predicted PFS at a prognostic level, the trial-level assessment did not show strong correlation (, confidence interval [CI]: 0.20–0.88;, CI: 0.0–0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI-PET-CR end-point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET-CR based surrogate end-points is still warranted. Progression-free survival (PFS) has been the regulatory primary end-point for recent phase III trials in first-line follicular lymphoma (FL), but requires prolonged follow-up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end-point for PFS. Our objective was to further evaluate surrogacy of CR measured by [ F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial-level surrogacy examining the association between treatment effects on EoI-PET-CR and PFS was evaluated using linear regression ( ) and bivariate Copula ( ) models. Although EoI-PET-CR strongly predicted PFS at a prognostic level, the trial-level assessment did not show strong correlation ( , confidence interval [CI]: 0.20-0.88; , CI: 0.0-0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI-PET-CR end-point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET-CR based surrogate end-points is still warranted. Summary Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end‐point for PFS. Our objective was to further evaluate surrogacy of CR measured by [ 18 F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial‐level surrogacy examining the association between treatment effects on EoI‐PET‐CR and PFS was evaluated using linear regression () and bivariate Copula () models. Although EoI‐PET‐CR strongly predicted PFS at a prognostic level, the trial‐level assessment did not show strong correlation (, confidence interval [CI]: 0.20–0.88; , CI: 0.0–0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI‐PET‐CR end‐point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET‐CR based surrogate end‐points is still warranted. Summary Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end‐point for PFS. Our objective was to further evaluate surrogacy of CR measured by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial‐level surrogacy examining the association between treatment effects on EoI‐PET‐CR and PFS was evaluated using linear regression (RWLS2) and bivariate Copula (RCopula2) models. Although EoI‐PET‐CR strongly predicted PFS at a prognostic level, the trial‐level assessment did not show strong correlation (RWLS2=0.56, confidence interval [CI]: 0.20–0.88; RCopula2=0.35, CI: 0.0–0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI‐PET‐CR end‐point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET‐CR based surrogate end‐points is still warranted. Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires prolonged follow‐up. Complete response (CR) at 30 months after initiation of induction treatment was validated as surrogate end‐point for PFS. Our objective was to further evaluate surrogacy of CR measured by [18F] fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging at the end of induction (EoI). Individual patient data were analysed from 1505 patients from five randomized trials. Trial‐level surrogacy examining the association between treatment effects on EoI‐PET‐CR and PFS was evaluated using linear regression (RWLS2) and bivariate Copula (RCopula2) models. Although EoI‐PET‐CR strongly predicted PFS at a prognostic level, the trial‐level assessment did not show strong correlation (RWLS2=0.56, confidence interval [CI]: 0.20–0.88; RCopula2=0.35, CI: 0.0–0.82). The high uncertainty in estimation was possibly due to the small number of trials and the population of patients with available PET data. Maintenance therapy affecting PFS beyond induction treatment, but not EoI‐PET‐CR end‐point, may have distorted the association between treatment effects. However, there will probably be a number of additional trials approaching completion with available PET response data. Refined evaluation of PET‐CR based surrogate end‐points is still warranted. |
| Author | Marcus, Robert Morschhauser, Franck Dixon, Jesse G. Nielsen, Tina Zheng, Jamie Shi, Qian Blum, Kristie A. Dimier, Natalie Evens, Andrew M. Federico, Massimo |
| Author_xml | – sequence: 1 givenname: Jesse G. orcidid: 0000-0002-6612-1564 surname: Dixon fullname: Dixon, Jesse G. email: dixon.jesse@mayo.edu organization: Mayo Clinic – sequence: 2 givenname: Natalie surname: Dimier fullname: Dimier, Natalie organization: Roche Products Ltd – sequence: 3 givenname: Tina surname: Nielsen fullname: Nielsen, Tina organization: Roche Products Ltd – sequence: 4 givenname: Jamie surname: Zheng fullname: Zheng, Jamie organization: Bristol‐Myers Squibb – sequence: 5 givenname: Robert surname: Marcus fullname: Marcus, Robert organization: King's College Hospital – sequence: 6 givenname: Franck surname: Morschhauser fullname: Morschhauser, Franck organization: University of Lille, CHU Lille – sequence: 7 givenname: Andrew M. surname: Evens fullname: Evens, Andrew M. organization: Rutgers Cancer Institute of New Jersey – sequence: 8 givenname: Massimo surname: Federico fullname: Federico, Massimo organization: Centro Oncologico Modenese, Universita di Modena e Reggio Emilia – sequence: 9 givenname: Kristie A. orcidid: 0000-0003-4229-2569 surname: Blum fullname: Blum, Kristie A. organization: Emory University – sequence: 10 givenname: Qian surname: Shi fullname: Shi, Qian organization: Mayo Clinic |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35491747$$D View this record in MEDLINE/PubMed https://hal.univ-lille.fr/hal-04159853$$DView record in HAL |
| BookMark | eNp1kcFu1DAQhi1URLcLB14AWeLSHtLasZ04x3a1ZUErgVA5W05sd71y4mAni3LjEfoSvBhPgsOWIiHhi0fjb_6Z8X8GTjrfaQBeY3SJ07mq97tLzHNcPgMLTAqW5ZjiE7BACJUZRpSfgrMY9whhghh-AU4JoxUuabkAP9adgt5A26mxGazvYO-jHUIKdGtjnDODb_19kP1ugo1ve6cHDYOOve-ihuef1nc_vz-sPl9AGaGEcQzB38uEGB9gn-KEzjIJMkHrGTjYg3SpZXrWB-vH6CY4dkPQqUylOudsMzoZoJvafudb-RI8N9JF_erxXoIvt-u71Sbbfnz3fnW9zRrCyzJTBilVmZxoI0ssc5YTqihrClYz2lQ5qXlK8pxTxE1Na2OokqaQqmJ1rVFFluDiqLuTTvTBtjJMwksrNtdbMecQxazijBxwYs-PbNrx66jjINJ_Ndo52em0ksgLxguGZnoJ3v6D7v0YurRJoniFES8R-du8CT7GoM3TBBiJ2WeRfBa_fU7sm0fFsW61eiL_GJuAqyPwzTo9_V9J3HzYHCV_AUZ5uG8 |
| CitedBy_id | crossref_primary_10_1080_10428194_2023_2226429 crossref_primary_10_1053_j_semnuclmed_2022_11_001 |
| Cites_doi | 10.1200/JCO.2016.70.8651 10.1200/JCO.2012.45.0866 10.1056/NEJMoa1805104 10.1002/pst.207 10.1200/JCO.2017.74.1652 10.1200/JCO.2006.09.2403 10.1056/NEJMoa1614598 10.1200/Jco.2018.77.9124 10.1200/JCO.2005.01.6071 10.1002/cncr.32289 10.1158/1078‐0432.CCR‐20‐1345 10.1093/jnci/djab187 10.1200/JCO.2013.54.8800 10.1016/S2352‐3026(14)70008‐0 10.1111/j.1467‐985X.2004.00293.x |
| ContentType | Journal Article |
| Copyright | 2022 British Society for Haematology and John Wiley & Sons Ltd. 2022 British Society for Haematology and John Wiley & Sons Ltd Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: 2022 British Society for Haematology and John Wiley & Sons Ltd. – notice: 2022 British Society for Haematology and John Wiley & Sons Ltd – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | NPM AAYXX CITATION 7T5 H94 7X8 1XC |
| DOI | 10.1111/bjh.18217 |
| DatabaseName | PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic Hyper Article en Ligne (HAL) |
| DatabaseTitle | PubMed CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | PubMed CrossRef AIDS and Cancer Research Abstracts |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2141 |
| EndPage | 337 |
| ExternalDocumentID | oai_HAL_hal_04159853v1 10_1111_bjh_18217 35491747 BJH18217 |
| Genre | shortCommunication Journal Article |
| GrantInformation_xml | – fundername: Celgene – fundername: F. Hoffmann‐La Roche – fundername: F. Hoffmann-La Roche |
| GroupedDBID | --- .3N .55 .GA .GJ .Y3 05W 0R~ 10A 1KJ 1OB 1OC 23N 24P 31~ 33P 36B 3O- 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8F7 8UM 930 A01 A03 AAESR AAEVG AAHHS AAKAS AANLZ AAONW AASGY AAXRX AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACBWZ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZCM ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFNX AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AHEFC AI. AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ASPBG ATUGU AVWKF AZBYB AZFZN AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CAG COF CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EGARE EJD EMOBN ESX EX3 F00 F01 F04 F5P FEDTE FUBAC FZ0 G-S G.N GODZA H.X HF~ HGLYW HVGLF HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LW6 LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N4W N9A NF~ O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D PALCI Q.N Q11 QB0 R.K RIWAO RJQFR ROL RX1 SAMSI SUPJJ TEORI UB1 V8K V9Y VH1 W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR X7M XG1 YFH YOC YUY ZGI ZXP ZZTAW ~IA ~WT NPM AAYXX CITATION 7T5 H94 7X8 1XC |
| ID | FETCH-LOGICAL-c3877-df0dd9f23efa71a25234d45c65b54c923b8a25828408fb4bff4daf6ad95bbe093 |
| IEDL.DBID | DR2 |
| ISSN | 0007-1048 |
| IngestDate | Tue Oct 15 15:47:03 EDT 2024 Fri Aug 16 05:26:06 EDT 2024 Thu Oct 10 18:46:36 EDT 2024 Fri Aug 23 03:48:47 EDT 2024 Sat Sep 28 08:20:00 EDT 2024 Sat Aug 24 00:59:10 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | surrogate end-point PET-CR follicular lymphoma previously untreated progression-free survival |
| Language | English |
| License | 2022 British Society for Haematology and John Wiley & Sons Ltd. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3877-df0dd9f23efa71a25234d45c65b54c923b8a25828408fb4bff4daf6ad95bbe093 |
| Notes | Funding information This analysis was supported by grants from Celgene and Roche. Data were transmitted directly from original study cooperative groups to the Mayo Clinic Statistical Data Center. Celgene and Roche supported organization and meetings of the FLASH group. Final analysis and publication of results were under the authority of the FLASH group. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4229-2569 0000-0002-6612-1564 |
| PMID | 35491747 |
| PQID | 2689108703 |
| PQPubID | 36395 |
| PageCount | 5 |
| ParticipantIDs | hal_primary_oai_HAL_hal_04159853v1 proquest_miscellaneous_2658650985 proquest_journals_2689108703 crossref_primary_10_1111_bjh_18217 pubmed_primary_35491747 wiley_primary_10_1111_bjh_18217_BJH18217 |
| PublicationCentury | 2000 |
| PublicationDate | July 2022 |
| PublicationDateYYYYMMDD | 2022-07-01 |
| PublicationDate_xml | – month: 07 year: 2022 text: July 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationSeriesTitle | British Journal of Haematology |
| PublicationTitle | British journal of haematology |
| PublicationTitleAlternate | Br J Haematol |
| PublicationYear | 2022 |
| Publisher | Blackwell Publishing Ltd Wiley |
| Publisher_xml | – name: Blackwell Publishing Ltd – name: Wiley |
| References | 2014; 1 2004; 167 2017; 35 2013; 31 2018; 379 2006; 5 2020; 26 2019; 125 2017; 377 2007; 25 2005; 23 2014; 32 2018; 36 2022; 114 e_1_2_8_13_1 e_1_2_8_14_1 e_1_2_8_15_1 e_1_2_8_16_1 e_1_2_8_3_1 e_1_2_8_2_1 e_1_2_8_5_1 e_1_2_8_4_1 e_1_2_8_7_1 e_1_2_8_6_1 e_1_2_8_9_1 e_1_2_8_8_1 e_1_2_8_10_1 e_1_2_8_11_1 e_1_2_8_12_1 |
| References_xml | – volume: 167 start-page: 103 year: 2004 end-page: 24 article-title: The validation of surrogate end points by using data from randomized clinical trials: a case‐study in advanced colorectal cancer publication-title: J R Stat Soc – volume: 26 start-page: 4468 issue: 17 year: 2020 end-page: 77 article-title: A three‐arm randomized phase II study of bendamustine/rituximab with bortezomib induction or lenalidomide continuation in untreated follicular lymphoma: ECOG‐ACRIN E2408 publication-title: Clin Cancer Res – volume: 1 start-page: e17 issue: 1 year: 2014 end-page: 27 article-title: Prognostic value of PET‐CT after first‐line therapy in patients with follicular lymphoma: a pooled analysis of central scan review in three multicentre studies publication-title: Lancet Haematol – volume: 25 start-page: 579 issue: 5 year: 2007 end-page: 86 article-title: Revised response criteria for malignant lymphoma publication-title: J Clin Oncol – volume: 36 start-page: 2593 issue: 25 year: 2018 article-title: Progression‐free survival as a surrogate end point for overall survival in first‐line diffuse large B‐cell lymphoma: an individual patient‐level analysis of multiple randomized trials (SEAL) publication-title: J Clin Oncol – volume: 36 start-page: 689 issue: 7 year: 2018 end-page: 96 article-title: Long‐term results of the FOLL05 trial comparing R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage symptomatic follicular lymphoma publication-title: J Clin Oncol – volume: 125 start-page: 3378 issue: 19 year: 2019 end-page: 89 article-title: Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high‐risk follicular lymphoma: CALGB 50904 (Alliance) publication-title: Cancer – volume: 23 start-page: 8664 issue: 34 year: 2005 end-page: 70 article-title: Disease‐free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials publication-title: J Clin Oncol – volume: 5 start-page: 173 issue: 3 year: 2006 end-page: 86 article-title: Surrogate threshold effect: an alternative measure for meta‐analytic surrogate endpoint validation publication-title: Pharm Stat – volume: 32 start-page: 3059 issue: 27 year: 2014 end-page: 68 article-title: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non‐Hodgkin lymphoma: the Lugano classification publication-title: J Clin Oncol – volume: 31 start-page: 1506 issue: 12 year: 2013 end-page: 13 article-title: R‐CVP versus R‐CHOP versus R‐FM for the initial treatment of patients with advanced‐stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi publication-title: J Clin Oncol – volume: 377 start-page: 1331 issue: 14 year: 2017 end-page: 44 article-title: Obinutuzumab for the first‐line treatment of follicular lymphoma publication-title: N Engl J Med – volume: 114 start-page: 60 issue: 1 year: 2022 end-page: 7 article-title: Re‐evaluating disease‐free survival as an endpoint vs overall survival in stage III adjuvant colon cancer trials publication-title: J Natl Cancer Inst – volume: 379 start-page: 934 issue: 10 year: 2018 end-page: 47 article-title: Rituximab plus lenalidomide in advanced untreated follicular lymphoma publication-title: N Engl J Med – volume: 35 start-page: 552 issue: 5 year: 2017 end-page: 60 article-title: Thirty‐month complete response as a surrogate end point in first‐line follicular lymphoma therapy: an individual patient‐level analysis of multiple randomized trials publication-title: J Clin Oncol – ident: e_1_2_8_2_1 doi: 10.1200/JCO.2016.70.8651 – ident: e_1_2_8_13_1 doi: 10.1200/JCO.2012.45.0866 – ident: e_1_2_8_16_1 doi: 10.1056/NEJMoa1805104 – ident: e_1_2_8_10_1 doi: 10.1002/pst.207 – ident: e_1_2_8_14_1 doi: 10.1200/JCO.2017.74.1652 – ident: e_1_2_8_5_1 doi: 10.1200/JCO.2006.09.2403 – ident: e_1_2_8_15_1 doi: 10.1056/NEJMoa1614598 – ident: e_1_2_8_8_1 doi: 10.1200/Jco.2018.77.9124 – ident: e_1_2_8_7_1 doi: 10.1200/JCO.2005.01.6071 – ident: e_1_2_8_11_1 doi: 10.1002/cncr.32289 – ident: e_1_2_8_12_1 doi: 10.1158/1078‐0432.CCR‐20‐1345 – ident: e_1_2_8_9_1 doi: 10.1093/jnci/djab187 – ident: e_1_2_8_3_1 doi: 10.1200/JCO.2013.54.8800 – ident: e_1_2_8_4_1 doi: 10.1016/S2352‐3026(14)70008‐0 – ident: e_1_2_8_6_1 doi: 10.1111/j.1467‐985X.2004.00293.x |
| SSID | ssj0013051 |
| Score | 2.4403737 |
| Snippet | Summary
Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but... Progression-free survival (PFS) has been the regulatory primary end-point for recent phase III trials in first-line follicular lymphoma (FL), but requires... Progression‐free survival (PFS) has been the regulatory primary end‐point for recent phase III trials in first‐line follicular lymphoma (FL), but requires... |
| SourceID | hal proquest crossref pubmed wiley |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 333 |
| SubjectTerms | Clinical trials follicular lymphoma Hematology Life Sciences Lymphoma Patients PET‐CR Positron emission tomography previously untreated progression‐free survival Regression analysis surrogate end‐point Survival Tomography |
| Title | End of induction positron emission tomography complete response (PET‐CR) as a surrogate for progression‐free survival in previously untreated follicular lymphoma |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fbjh.18217 https://www.ncbi.nlm.nih.gov/pubmed/35491747 https://www.proquest.com/docview/2689108703 https://search.proquest.com/docview/2658650985 https://hal.univ-lille.fr/hal-04159853 |
| Volume | 198 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VHhAX3o8tBRnEoRyy2sSPJOJUylariiJUtVIPSJGfamGbVMmmUjnxE_gT_DF-CWPnAQUhIW6RPZYde8b-xv48BnhBBZdCax3lIucR4lsVKUpNxKnKaKxUnBq_D7n_TiyO2N4xP16DV8NdmC4-xLjh5i0jzNfewKVqfjFy9fFkiuA49jfJY5p6Otebg-TnCcKM96_lpTjVsKyPKuRZPGPJK2vRtRPPhPwTZl5FrWHZ2b0FH4YGd2yTT9N2pab682-xHP_zj27DzR6Oku1Of-7Ami3vwvX9_sD9Hnybl4ZUjqDn3oWZJYHlVeOHfyjOb7WRVXXWx70mgaCOMJzUHfXWkq3388PvX77uHLwksiGSNG1dV37rjiBaJoEd1kUGQSFXW-sFLk5R_bFKzMZlu2qb5SVpy0CJtwbLLZengT1Llpeoi9WZvA9Hu_PDnUXUv-wQaZqlaWTczJjcJdQ6mcYyQW-YGca14IozjZhTZZiIziCbZU4x5Rwz0glpcq6UneX0AayXVWkfAcmFdTqmXAnmGOdYGNffWKWCa5OITEzg-TDGxXkXwKMYHB_s8CJ0OArh6I_5PuT2Yvtt4dN8CIMcMc1FPIHNQTmK3tCbAqtAwIWTHp3AszEbB8Cfu8jSYh-hDM98oMKMT-Bhp1RjVRT9c3QKsQVbQTX-3sbi9d4ifGz8u-hjuJH46xqBXrwJ66u6tU8QRK3U02AtPwCltxtv |
| link.rule.ids | 230,315,783,787,888,1378,27936,27937,46306,46730 |
| linkProvider | Wiley-Blackwell |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwEB61RYJeyj8sFDCIQzlktYl_kkhcStkqlN0KVVupFxTFsa22bJMqu6lUTjwCL8GL8SSMnR8oCAlxi-Kx7Ngz9jfjyWeAl1TwTOR57sUi5h7iW-lJSpXHqYyoL6UfKhuHnO6L5JDtHfGjFXjd_QvT8EP0ATdrGW69tgZuA9K_WLk8PR4iOvbDVbiG5k7txQ1vD4KfZwgj3t6XF-Jiw6KWV8jm8fRVr-xGq8c2F_JPoHkVt7qNZ_cmfOy63OSbfBrWSznMP__G5vi_33QLNlpESrYbFboNK7q4A9en7Zn7Xfg2LhQpDUHnvWGaJS7Rq8IHe1ecjbaRZXnWUl8Tl6OOSJxUTfatJlsfxrPvX77uHLwi2YJkZFFXVWmjdwQBM3EJYg05CAqZSmsrcHGCFoBNYjHu3GW9mF-SunBZ8Vphvfn8xCXQkvklqmN5lt2Dw93xbCfx2ssdvJxGYegpM1IqNgHVJgv9LECHmCnGc8ElZznCThnhS_QH2SgykkljmMqMyFTMpdSjmN6HtaIs9EMgsdAm9ymXghnGOVbGLdiXoeC5CkQkBvCim-T0vOHwSDvfBwc8dQOOQjj9fbll3U62J6l9Z1kMYoQ1F_4ANjvtSFtbX6TYBGIuXPfoAJ73xTgB9uglKzSOEcrwyHIVRnwADxqt6pui6KKjX4g92HK68fc-pm_2Evfw6N9Fn8GNZDadpJN3--8fw3pg_95w2cabsLasav0EMdVSPnWm8wMstR-H |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtQwFL1qi1Sx4f2YUsAgFmWR0SR-JBGrUmY0lLaqqlbqAimyY1stnSZVZlKprPgEfoIf40u4dh5QEBJiF8XXsmNf2-faJ8cAr6jgUuR5HqQi5QHiWxUoSnXAqUpoqFQYa7cPubsnpkds-5gfL8Gb7l-YRh-i33BzI8PP126AX2j7yyBXn06GCI7DeBluMIHI1yGig-jnEcKIt9flxTjXsKSVFXI0nj7rtcVo-cRRIf_Emddhq193JrfhY1fjhm5yNqwXaph__k3M8T8_6Q7cavEo2Wwc6C4smeIerO62J-734du40KS0BEP3RmeWeJpXhQ_upji310YW5XkrfE08Qx1xOKka7q0hG_vjw-9fvm4dvCZyTiSZ11VVur07gnCZeHpYIw2CRrYyxhlcnqL_Y5GYjOt2Wc9nV6QuPCfeaMw3m516-iyZXaEzlufyARxNxodb06C92iHIaRLHgbYjrVMbUWNlHMoIw2GmGc8FV5zlCDpVgi8xGmSjxCqmrGVaWiF1ypUyo5Q-hJWiLMxjIKkwNg8pV4JZxjlmxgU4VLHguY5EIgbwsuvj7KJR8Mi6yAcbPPMNjkbY-32609yebu5k7p3TMEgR1FyGA1jvnCNrR_o8wyIQceGsRwfwok_GDnAHL7Iw2EZowxOnVJjwATxqnKovimKAjlEh1mDDu8bf65i93Z76h7V_N30Oq_vvJtnO-70PT-Bm5H7d8FTjdVhZVLV5ioBqoZ75gfMDxNIeNg |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=End+of+induction+positron+emission+tomography+complete+response+%28PET-CR%29+as+a+surrogate+for+progression-free+survival+in+previously+untreated+follicular+lymphoma&rft.jtitle=British+journal+of+haematology&rft.au=Dixon%2C+Jesse+G&rft.au=Dimier%2C+Natalie&rft.au=Nielsen%2C+Tina&rft.au=Zheng%2C+Jamie&rft.date=2022-07-01&rft.eissn=1365-2141&rft.volume=198&rft.issue=2&rft.spage=333&rft.epage=337&rft_id=info:doi/10.1111%2Fbjh.18217&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |